Janux Therapeutics
JANX | NASDAQ
$10.92
-$0.45 (-3.96%)
At close: Nov 16, 2026, 4:00 PM ET
$11.12
+$0.20 (+1.83%)
After-hours:
Nov 16, 2026, 7:35 PM ET
Janux Therapeutics Company Profile
Company profile explainedCompany Profile
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.
Key Executives
| Name | Position |
|---|---|
| David Alan Campbell | President, Co-Founder, CEO & Director |
| Charles Winter | Chief Technical Officer |
| James Pennington | General Counsel & Corporate Secretary |
| Janeen Doyle | Chief Corporate & Business Development Officer |
| Mandie Forman-Sklansky | Head of Human Resources |
| Maria Dobek | Vice President of Accounting |
| Matt Whitmire | Vice President of Finance |
| Thomas Diraimondo | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 13, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 06, 2026 | 10-Q | Quarterly Report |
| Aug 06, 2026 | 8-K | Current Report |
| Jul 31, 2026 | 4 | Filing |
| Jul 28, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jul 10, 2026 | 4 | Filing |
| Jun 23, 2026 | 8-K | Current Report |
| Jun 12, 2026 | 4 | Filing |
| Jun 12, 2026 | 4 | Filing |
Janux Therapeutics
| Country | United States |
| IPO Date | Jun 11, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 113 |
| CEO | David Alan Campbell |
Contact Details
10955 Vista Sorrento Parkway San Diego,
California 92130 United States
Stock Details
| Ticker Symbol | JANX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001817713 |
| CUSIP Number | 47103J105 |
| ISIN Number | US47103J1051 |
| SIC Code | 2834 |
Recent News
- 8 days ago / businesswire.comJanux Therapeutics Announces Positive Initial Phase 1 Data for JANX011 in Healthy Volunteers, Supporting Planned Development in Patients with Autoimmune Disease
- 11 days ago / zacks.comJanux Therapeutics, Inc. (JANX) Reports Q3 Loss, Beats Revenue Estimates
- 2 months ago / businesswire.comJanux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013
- 3 months ago / zacks.comJANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know
Add to Watchlist
Select watchlists to add or remove JANX